Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations

Infection, Genetics and Evolution

Volumn 10, Issue 1, 2010, Pages 60-67

  Benish, Rebekah L ^a   Rodriguez, Benigno ^a   Zimmerman, Peter A ^a   Mehlotra, Rajeev K ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABCB1; Anti HIV drugs; HIV negative; HIV positive; MDR1; North American ethnic groups; North American populations; P glycoprotein; Protease inhibitors

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEGRO; NONHUMAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; POPULATION DIFFERENTIATION; PRIORITY JOURNAL; RACEMIC MIXTURE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ALLELES; COHORT STUDIES; DNA; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENES, MDR; GENETIC VARIATION; GENETICS, POPULATION; GENOTYPE; HAPLOTYPES; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NORTH AMERICA; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 72149085454     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.09.018     Document Type: Article

References (75)

1. + T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 12 (1996) 1457-1462
2. Bleiber G., May M., Suarez C., Martinez R., Marzolini C., Egger M., and Telenti A. MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J. Infect. Dis. 189 (2004) 583-586
3. Bodor M., Kelly E.J., and Ho R.J. Characterization of the human MDR1 gene. AAPS J. 7 (2005) E1-5
4. Bonnen P.E., Wang P.J., Kimmel M., Chakraborty R., and Nelson D.L. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res. 12 (2002) 1846-1853
5. Burk O., Arnold K.A., Geick A., Tegude H., and Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386 (2005) 503-513
6. Camus M., Delomenie C., Didier N., Faye A., Gil S., Dauge M.C., Mabondzo A., and Farinotti R. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta 27 (2006) 699-706
7. Cavaco I., Stromberg-Norklit J., Kaneko A., Msellem M.I., Dahoma M., Ribeiro V.L., Bjorkman A., and Gil J.P. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur. J. Clin. Pharmacol. 61 (2005) 15-18
8. Chandler B., Almond L., Ford J., Owen A., Hoggard P., Khoo S., and Back D. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. AIDS 33 (2003) 551-556
9. Cianfriglia M., Dupuis M.L., Molinari A., Verdoliva A., Costi R., Galluzzo C.M., Andreotti M., Cara A., Di Santo R., and Palmisano L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4 (2007) 17
10. Colombo S., Soranzo N., Rotger M., Sprenger R., Bleiber G., Furrer H., Buclin T., Goldstein D., Decosterd L., and Telenti A. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics 15 (2005) 599-608
11. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J. AIDS 45 Suppl. 1 (2007) S14-18
12. Cressey T.R., and Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect. Genet. Evol. 7 (2007) 333-342
13. de la Tribonniere X., Broly F., Deuffic-Burban S., Bocket L., Ajana F., Viget N., Melliez H., Mouton Y., and Yazdanpanah Y. ABCB1 allele polymorphism is associated with virological efficacy in naive HIV-infected patients on HAART containing nonboosted PIs but not boosted PIs. HIV Clin. Trials 9 (2008) 192-201
14. Dorado P., Suarez-Kurtz G., and LLerena A. Pharmacogenetics of cytochrome P450 in Hispanic populations. In: Suarez-Kurtz G. (Ed). Pharmacogenomics in Admixed Populations (2007), Landes Bioscience, Austin, TX 60-74
15. Easterbrook P.J., Phillips A.N., Hill T., Matthias R., Fisher M., Gazzard B., Gilson R., Scullard G., Johnson M., Dunn D.T., Orkin C., Anderson J., Schwenk A., Leen C., and Sabin C.A. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 9 (2008) 47-56
16. Eichelbaum M., Fromm M.F., and Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26 (2004) 180-185
17. Estrela R.C., Ribeiro F.S., Carvalho R.S., Gregorio S.P., Dias-Neto E., Struchiner C.J., and Suarez-Kurtz G. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9 (2008) 267-276
18. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., and Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
19. Ford J., Meaden E.R., Hoggard P.G., Dalton M., Newton P., Williams I., Khoo S.H., and Back D.J. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J. Antimicrob. Chemother. 52 (2003) 354-358
20. Fung K.L., and Gottesman M.M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794 (2009) 860-871
21. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., and Inui K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12 (2002) 451-457
22. Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., De Gruttola V., Pollard R.B., Merigan T.C., Hirsch M.S., George Jr. A.L., Donahue J.P., and Kim R.B. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192 (2005) 1931-1942
23. Haas D.W., Bartlett J.A., Andersen J.W., Sanne I., Wilkinson G.R., Hinkle J., Rousseau F., Ingram C.D., Shaw A., Lederman M.M., and Kim R.B. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis. 43 (2006) 783-786
24. Hendrickson S.L., Jacobson L.P., Nelson G.W., Phair J.P., Lautenberger J., Johnson R.C., Kingsley L., Margolick J.B., Detels R., Goedert J.J., and O'Brien S.J. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J. AIDS 48 (2008) 263-271
25. Huang R.S., Duan S., Kistner E.O., Zhang W., Bleibel W.K., Cox N.J., and Dolan M.E. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet. Genomics 18 (2008) 545-549
26. Jorajuria S., Dereuddre-Bosquet N., Naissant-Storck K., Dormont D., and Clayette P. Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages. Antimicrob. Agents Chemother. 48 (2004) 1889-1891
27. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., Lan L.B., Schuetz J.D., Schuetz E.G., and Wilkinson G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70 (2001) 189-199
28. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., and Gottesman M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
29. Kitahata M.M., Gange S.J., Abraham A.G., Merriman B., Saag M.S., Justice A.C., Hogg R.S., Deeks S.G., Eron J.J., Brooks J.T., Rourke S.B., Gill M.J., Bosch R.J., Martin J.N., Klein M.B., Jacobson L.P., Rodriguez B., Sterling T.R., Kirk G.D., Napravnik S., Rachlis A.R., Calzavara L.M., Horberg M.A., Silverberg M.J., Gebo K.A., Goedert J.J., Benson C.A., Collier A.C., Van Rompaey S.E., Crane H.M., McKaig R.G., Lau B., Freeman A.M., and Moore R.D. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl. J. Med. 360 (2009) 1815-1826
30. Kosoy R., Nassir R., Tian C., White P.A., Butler L.M., Silva G., Kittles R., Alarcon-Riquelme M.E., Gregersen P.K., Belmont J.W., De La Vega F.M., and Seldin M.F. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum. Mutat. 30 (2009) 69-78
31. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., Stryke D., Ferrin T.E., DeYoung J., Taylor T., Carlson E.J., Herskowitz I., Giacomini K.M., and Clark A.G. Sequence diversity and haplotype structure in the human ABCB1 (MDR1 multidrug resistance transporter) gene. Pharmacogenetics 13 (2003) 481-494
32. la Porte C.J., Li Y., Beique L., Foster B.C., Chauhan B., Garber G.E., Cameron D.W., and van Heeswijk R.P. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin. Pharmacol. Ther. 82 (2007) 389-395
33. Lamba J., Strom S., Venkataramanan R., Thummel K.E., Lin Y.S., Liu W., Cheng C., Lamba V., Watkins P.B., and Schuetz E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. 79 (2006) 325-338
34. Lee C.G., Ramachandra M., Jeang K.T., Martin M.A., Pastan I., and Gottesman M.M. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14 (2000) 516-522
35. Leschziner G., Zabaneh D., Pirmohamed M., Owen A., Rogers J., Coffey A.J., Balding D.J., Bentley D.B., and Johnson M.R. Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet. Genomics 16 (2006) 439-450
36. Leschziner G.D., Andrew T., Pirmohamed M., and Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7 (2007) 154-179
37. Loeuillet C., Weale M., Deutsch S., Rotger M., Soranzo N., Wyniger J., Lettre G., Dupre Y., Thuillard D., Beckmann J.S., Antonarakis S.E., Goldstein D.B., and Telenti A. Promoter polymorphisms and allelic imbalance in ABCB1 expression. Pharmacogenet. Genomics 17 (2007) 951-959
38. Lucia M.B., Rutella S., Leone G., Larocca L.M., Vella S., and Cauda R. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J. AIDS 30 (2002) 369-378
39. Ma Q., Brazeau D., Zingman B.S., Reichman R.C., Fischl M.A., Gripshover B.M., Venuto C.S., Slish J.C., DiFrancesco R., Forrest A., and Morse G.D. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 8 (2007) 227-235
40. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75 (2004) 13-33
41. Meaden E.R., Hoggard P.G., Maher B., Khoo S.H., and Back D.J. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res. Hum. Retroviruses 17 (2001) 1329-1332
42. Mehlotra R.K., Ziats M.N., Bockarie M.J., and Zimmerman P.A. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 62 (2006) 267-275
43. Mehlotra R.K., Bockarie M.J., and Zimmerman P.A. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. 64 (2007) 391-395
44. Mehlotra R.K., Bockarie M.J., and Zimmerman P.A. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur. J. Clin. Pharmacol. 63 (2007) 1-8
45. Morita N., Yasumori T., and Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65 (2003) 1843-1852
46. Owen A., Chandler B., Back D.J., and Khoo S.H. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir. Ther. 9 (2004) 819-821
47. Owen A., Chandler B., and Back D.J. The implications of P-glycoprotein in HIV: friend or foe?. Fundam. Clin. Pharmacol. 19 (2005) 283-296
48. Owen A., Goldring C., Morgan P., Chadwick D., Park B.K., and Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br. J. Clin. Pharmacol. 59 (2005) 365-370
49. Owen A., Pirmohamed M., Khoo S.H., and Back D.J. Pharmacogenetics of HIV therapy. Pharmacogenet. Genomics 16 (2006) 693-703
50. Ozawa S., Soyama A., Saeki M., Fukushima-Uesaka H., Itoda M., Koyano S., Sai K., Ohno Y., Saito Y., and Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 19 (2004) 83-95
51. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl. J. Med. 338 (1998) 853-860
52. Parra E.J., Marcini A., Akey J., Martinson J., Batzer M.A., Cooper R., Forrester T., Allison D.B., Deka R., Ferrell R.E., and Shriver M.D. Estimating African American admixture proportions by use of population-specific alleles. Am. J. Hum. Genet. 63 (1998) 1839-1851
53. Parra E.J. Admixture in North America. In: Suarez-Kurtz G. (Ed). Pharmacogenomics in Admixed Populations (2007), Landes Bioscience, Austin, TX 28-46
54. Raviv Y., Puri A., and Blumenthal R. P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane. FASEB J. 14 (2000) 511-515
55. Ritchie M.D., Haas D.W., Motsinger A.A., Donahue J.P., Erdem H., Raffanti S., Rebeiro P., George A.L., Kim R.B., Haines J.L., and Sterling T.R. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect. Dis. 43 (2006) 779-782
56. Rodriguez-Novoa S., Barreiro P., Jimenez-Nacher I., and Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 6 (2006) 234-245
57. Sai K., Kaniwa N., Itoda M., Saito Y., Hasegawa R., Komamura K., Ueno K., Kamakura S., Kitakaze M., Shirao K., Minami H., Ohtsu A., Yoshida T., Saijo N., Kitamura Y., Kamatani N., Ozawa S., and Sawada J. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13 (2003) 741-757
58. Saitoh A., Singh K.K., Powell C.A., Fenton T., Fletcher C.V., Brundage R., Starr S., and Spector S.A. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS (London, England) 19 (2005) 371-380
59. Saracino A., Gianotti N., Marangi M., Cibelli D.C., Galli A., Punzi G., Monno L., Lazzarin A., and Angarano G. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J. Med. Virol. 80 (2008) 1695-1706
60. Siccardi M., D'Avolio A., Baietto L., Gibbons S., Sciandra M., Colucci D., Bonora S., Khoo S., Back D.J., Di Perri G., and Owen A. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 47 (2008) 1222-1225
61. Song P., Lamba J.K., Zhang L., Schuetz E., Shukla N., Meibohm B., and Yates C.R. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol. 46 (2006) 373-379
62. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., and Lee C.G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12 (2002) 437-450
63. Tang K., Wong L.P., Lee E.J., Chong S.S., and Lee C.G. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13 (2004) 783-797
64. Taniguchi S., Mochida Y., Uchiumi T., Tahira T., Hayashi K., Takagi K., Shimada M., Maehara Y., Kuwano H., Kono S., Nakano H., Kuwano M., and Wada M. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol. Cancer Ther. 2 (2003) 1351-1359
65. Telenti A., and Zanger U.M. Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 227-256
66. Turriziani O., Gianotti N., Falasca F., Boni A., Vestri A.R., Zoccoli A., Lazzarin A., and Antonelli G. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J. Med. Virol. 80 (2008) 766-771
67. Veiga M.I., Asimus S., Ferreira P.E., Martins J.P., Cavaco I., Ribeiro V., Hai T.N., Petzold M.G., Bjorkman A., Ashton M., and Gil J.P. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur. J. Clin. Pharmacol. 65 (2009) 355-363
68. Verstuyft C., Marcellin F., Morand-Joubert L., Launay O., Brendel K., Mentre F., Peytavin G., Gerard L., Becquemont L., and Aboulker J.P. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS (London, England) 19 (2005) 2127-2131
69. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15 (2005) 693-704
70. Wang H., Ding K., Zhang Y., Jin L., Kullo I.J., and He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet. Genomics 17 (2007) 667-678
71. Wilson J.F., Weale M.E., Smith A.C., Gratrix F., Fletcher B., Thomas M.G., Bradman N., and Goldstein D.B. Population genetic structure of variable drug response. Nat. Genet. 29 (2001) 265-269
72. Woodahl E.L., Yang Z., Bui T., Shen D.D., and Ho R.J. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (London, England) 19 (2005) 1617-1625
73. Xu P., Jiang Z.P., Zhang B.K., Tu J.Y., and Li H.D. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 82 (2008) 221-227
74. Yang Z., Wu D., Bui T., and Ho R.J. A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J. Pharmacol. Exp. Ther. 327 (2008) 474-481
75. Zimmerman P.A., Woolley I., Masinde G.L., Miller S.M., McNamara D.T., Hazlett F., Mgone C.S., Alpers M.P., Genton B., Boatin B.A., and Kazura J.W. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13973-13977